David R. Wise, MD, PhD

Articles

Dr. Wise on Unmet Needs in the Standard of Care in Prostate Cancer

July 25th 2022

David R. Wise, MD, PhD, discusses unmet needs in the standard of care in prostate cancer.

Dr. Wise Discusses Challenges With Immunotherapy in Prostate Cancer

February 22nd 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses challenges with immunotherapy in prostate cancer.

Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

February 14th 2018

David R. Wise, MD, PhD assistant professor in the Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses the FDA approval of apalutamide (ARN-509) for the treatment of patients with non-metastatic castration-resistant prostate cancer (CRPC).

Dr. Wise on AR-Directed Therapy for Prostate Cancer

February 3rd 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses advancements with androgen receptor (AR)-directed therapy for patients with prostate cancer.

Dr. Wise on the Development of Precision Medicine in Prostate Cancer

January 30th 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses ongoing trials at NYU that are investigating precision oncology hypotheses.